on Friday said that European regulators had approved the use of its urinary drug Yentreve for the treatment of moderate to severe stress urinary incontinence (SUI) in women.
SUI is the accidental leakage of urine during physical activities such as sneezing, coughing, laughing, lifting or exercising, and it affects nearly 15 million American adult women, according to the company.
The Food and Drug Administration issued an approvable letter for Yentreve in August 2003. Lilly and its partner,
, expect FDA in the first half of 2005.
Shares gained 49 cents, or 0.8%, to $62.55.